BenevolentAI (previously Stratified Medical) is a leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development.
BenevolentAI is the global leader in the development and application of artificial intelligence (“AI”) for scientific innovation. It aims to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases.
BenevolentAI(originally as Stratified Medical) was founded in 2013 by Ken Mulvany. The company changed its name from Stratified Medical to benevolent.ai on September 2016. The company has it's headquarter in London, Greater London with offices in Cambridge, UK & NY, US.
BenevolentAI builds and applies AI to the entire drug discovery and development process. The technology unlocks what is not known by creating new ideas based on established facts to provide a different understanding of disease, which leads to inventive steps and real insights that drive the development of new medicines and treatments.
BenevolentAI is backed by top tier investors including Woodford Investment Management & Lansdowne Partners.